A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04137536

Recruitment Status : Active, not recruiting

First Posted : October 24, 2019

Last Update Posted : October 10, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

University of Virginia

Information provided by (Responsible Party):

Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	April 2023
Estimated Study Completion Date :	April 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Park JA, Santich BH, Xu H, Lum LG, Cheung NV. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. J Immunother Cancer. 2021 May;9(5):e002222. doi: 10.1136/jitc-2020-002222.

To Top